M42 and Juvenescence join forces to supercharge AI drug discovery

At the latest Abu Dhabi Global Health Week, M42 announced a bold new move: a strategic partnership — and a significant investment — in Juvenescence, a top-tier biotech player focused on longevity. This isn't just about backing another drug developer. It's about pushing the limits of how long — and how well — we can live, using the raw power of artificial intelligence.

As Hasan Jasem Al Nowais, M42's Group CEO, put it: "This is not just about innovation, it's about impact — on lives, on science and on the future of health."

How does it work?

The partnership blends M42's serious chops in genomics, biobanking, and clinical trials with Juvenescence's prowess in drug development and AI-fueled discovery.

• Together, they'll create a pipeline of new medicines aimed at age-related and high-need diseases.
• AI will play a starring role, helping identify new drug targets and speed up development timelines.
• A Joint Steering Committee, made up of execs from both firms, will keep the ship sailing smoothly.

Juvenescence brings some serious brainpower to the table — its leadership team has over 150 years of combined experience in getting drugs from idea to reality. And M42? They've already sequenced more than 800,000 genomes through the Emirati Genome Project and house nearly a million samples in their Abu Dhabi Biobank. That's not just data — it's a goldmine for breakthroughs.

Why does it matter?

Because time is precious — and so is health. As the global population ages, we're seeing more demand for treatments that don't just add years, but quality years. That's where longevity science steps in.

Dr. Fahed Al Marzooqi, who heads M42's AI Life Sciences platform, didn't mince words: "By uniting AI innovation with biotech expertise, we're not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress."

• This isn't pie-in-the-sky research — it's about getting real therapies to real people, faster.
• It's about making Abu Dhabi a world leader in life sciences.
• And it's about putting AI to work in the lab, not just in your phone.

The context

M42 has just reorganized itself into a sharper, more integrated force for health innovation, and this deal is the first major swing under that new structure. The partnership also plugs directly into Abu Dhabi's bigger-picture vision: becoming a global destination for AI-powered health tech and drug development.

It's worth noting that M42 isn't doing this in a vacuum. Its work with the Emirati Genome Project and the Department of Health Abu Dhabi has already laid a rich foundation for precision medicine. This latest move? It's like pouring jet fuel on a fire that was already burning bright.

Dr. Richard Marshall of Juvenescence summed it up best: "Our work together will enable the creation of a unique pipeline of innovative therapeutics... and improve the healthspan of patients globally."